HI-Bio appoints Dr. Sunil Agarwal to its Board of Directors and announces Dr. Uptal Patel as CMO

– USA, CA –  Human Immunology Biosciences, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases, today announced the appointment of Dr. Sunil Agarwal (M.D.) to its Board of Directors.

“We are thrilled to have someone of Sunil’s caliber join HI-Bio’s Board of Directors. His deep experience in clinical development and his impressive track record of shepherding new drugs through approval will be highly relevant to advancing our pipeline. We are delighted to welcome Sunil to the Board,” said Board Chairman, Paul Berns.

The company also announced the appointment of Dr. Uptal Patel (M.D.) as CMO.

About Dr. Sunil Agarwal

Sunil Agarwal was most recently EVP, Head of Development, and CMO at Sana Biotechnology. Before Sana, he was President of Research and Development at Juno Therapeutics and a Partner at Sofinnova, a Menlo Park, California-based biotech-focused investment firm. He is also a former EVP and CMO of Ultragenyx and served in various leadership roles at Genentech for more than a decade, leading the approval of multiple therapies including RITUXAN, ACTEMRA, LUCENTIS, and XOLAIR.

Dr. Agarwal completed his residency at Children’s National Medical Center, Washington, D.C., and practiced in the CNMC Pediatric Emergency Department. He obtained his B.S. in neurobiology from Cornell University and earned his M.D. from Tufts University School of Medicine.

About Dr. Uptal Patel

Dr. Patel joins HI-Bio from AstraZeneca where he served as the Head of Clinical Renal and Executive Group Director in Early Cardiovascular, Renal and Metabolism. In these roles, Dr. Patel led early clinical strategy and development for a wide range of therapies that address several kidney diseases, including ways to advance precision medicine approaches. Before joining AstraZeneca, he was Executive Director of Clinical Research at Gilead Sciences, leading the global clinical development of novel therapies for kidney diseases that address inflammatory pathways.

Previously, Dr. Patel was faculty in the adult and pediatric nephrology divisions at Duke University, a member of the Duke Clinical Research Institute, and a transplant nephrologist who took care of patients of all ages. There, he led several multidisciplinary translational research efforts and a broad-based research program focused on improving the detection and management of kidney disease.

He obtained his B.S. in Chemistry and Biochemistry from the University of California San Diego and earned his M.D. from the University of California San Francisco. Dr. Patel completed his residency and fellowship training at the University of Michigan.

About HI-Bio

Human Immunology Biosciences, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision medicines for people suffering from immune-mediated diseases. HI-Bio is leading clinical immunology into its next chapter with more targeted therapies that target cellular drivers of disease.

For more information: https://hibio.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.